| __timestamp | Insmed Incorporated | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 31073000 | 1860000 |
| Thursday, January 1, 2015 | 43216000 | 2963000 |
| Friday, January 1, 2016 | 50679000 | 6961000 |
| Sunday, January 1, 2017 | 79171000 | 11779000 |
| Monday, January 1, 2018 | 168218000 | 13697000 |
| Tuesday, January 1, 2019 | 210796000 | 15749000 |
| Wednesday, January 1, 2020 | 203613000 | 18638000 |
| Friday, January 1, 2021 | 234273000 | 27196000 |
| Saturday, January 1, 2022 | 265784000 | 31739000 |
| Sunday, January 1, 2023 | 344501000 | 33491000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Insmed Incorporated and Protagonist Therapeutics, Inc. have shown contrasting trends in this area from 2014 to 2023. Insmed's SG&A expenses have surged by over 1,000%, reflecting its aggressive growth strategy. In contrast, Protagonist Therapeutics has maintained a more conservative approach, with expenses increasing by approximately 1,700% but from a much smaller base.
Insmed's expenses peaked in 2023, reaching nearly 10 times their 2014 levels, indicating significant investment in operations and expansion. Meanwhile, Protagonist's expenses, though rising, remain a fraction of Insmed's, suggesting a focus on lean operations. This divergence highlights the strategic choices companies make in balancing growth and cost management. Investors and stakeholders should consider these trends when evaluating the long-term sustainability and strategic direction of these biotech firms.
Eli Lilly and Company or Insmed Incorporated: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Protagonist Therapeutics, Inc.
Breaking Down SG&A Expenses: Johnson & Johnson vs Insmed Incorporated
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Insmed Incorporated
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and Protagonist Therapeutics, Inc.
Insmed Incorporated or Verona Pharma plc: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Insmed Incorporated or Travere Therapeutics, Inc.
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Protagonist Therapeutics, Inc. and Geron Corporation
Comparing SG&A Expenses: Protagonist Therapeutics, Inc. vs MannKind Corporation Trends and Insights